Atorlip 10 is a prescription medication containing atorvastatin calcium, specifically formulated to manage elevated cholesterol levels and support cardiovascular health. As a member of the statin class, it works by inhibiting an enzyme in the liver responsible for cholesterol production, thereby reducing low-density lipoprotein (LDL) and triglycerides while increasing high-density lipoprotein (HDL). This medication is indicated for patients with hypercholesterolemia, those at risk of cardiovascular events, and individuals with familial hypercholesterolemia. Proper use under medical supervision can significantly lower the risk of heart attack, stroke, and arterial diseases.

Features

• Active ingredient: Atorvastatin calcium 10 mg
• Pharmaceutical form: Film-coated tablets
• Pack size: 30 tablets per blister
• Manufacturer: Accord Healthcare
• Requires prescription
• Storage: Room temperature (below 30°C)

Benefits

• Significantly reduces LDL (“bad”) cholesterol levels by up to 50% with proper adherence
• Lowers triglyceride levels while modestly increasing HDL (“good”) cholesterol
• Reduces risk of myocardial infarction and ischemic stroke in at-risk patients
• Slows progression of atherosclerosis and coronary artery disease
• May reduce need for invasive cardiac procedures in stable patients
• Provides 24-hour lipid-lowering effect with once-daily dosing

Common use

Atorlip 10 is primarily prescribed for patients diagnosed with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia. It is also indicated for mixed dyslipidemia and to prevent cardiovascular events in patients with multiple risk factors. Clinical guidelines recommend statin therapy for adults with LDL-C levels above 190 mg/dL, those with diabetes aged 40-75 years, and individuals with established cardiovascular disease. The medication is often combined with therapeutic lifestyle changes, including heart-healthy diet and regular physical activity.

Dosage and direction

The recommended starting dose is 10 mg or 20 mg once daily, with Atorlip 10 representing the lower strength option. Dosage may be adjusted at 2-4 week intervals based on lipid response and tolerability, up to a maximum of 80 mg daily. Administration should occur at the same time each day, with or without food. Tablets should be swallowed whole with water and not crushed or chewed. For optimal absorption consistency, many clinicians recommend evening administration, though chronotherapy considerations should be discussed with the prescribing physician.

Precautions

Liver function tests should be performed before initiation and periodically during treatment. Patients should report any unexplained muscle pain, tenderness, or weakness immediately. Caution is advised in elderly patients, those with renal impairment, and individuals consuming substantial quantities of alcohol. Atorlip 10 may increase HbA1c and fasting serum glucose levels. Ophthalmologic examinations are recommended if visual changes occur. The medication should be temporarily discontinued in patients experiencing major surgery, trauma, or severe metabolic disorders.

Contraindications

Atorlip 10 is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases. It must not be used during pregnancy, breastfeeding, or in women of childbearing potential not using adequate contraception. Additional contraindications include hypersensitivity to atorvastatin or any component of the formulation, concurrent use with strong CYP3A4 inhibitors, and patients with acute porphyria.

Possible side effects

Common adverse reactions (≥1%) include headache, myalgia, arthralgia, nausea, diarrhea, and constipation. Less frequently reported effects include elevated liver enzymes, insomnia, and rash. Serious but rare side effects include rhabdomyolysis with renal impairment, hepatotoxicity, and immune-mediated necrotizing myopathy. Approximately 1-3% of patients may experience mild, transient creatine kinase elevations. Pancreatitis and peripheral neuropathy have been reported in post-marketing surveillance.

Drug interaction

Atorlip 10 undergoes metabolism primarily through CYP3A4, resulting in significant interactions with:

• Strong CYP3A4 inhibitors: clarithromycin, itraconazole, HIV protease inhibitors (increased atorvastatin exposure)
• Gemfibrozil and other fibrates (increased risk of myopathy)
• Niacin (>1 g/day), cyclosporine, erythromycin
• Warfarin (monitor INR closely)
• Oral contraceptives containing ethinyl estradiol and norgestrel
• Digoxin (monitor levels)
• Colchicine (increased risk of myopathy)

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed administration. Consistent daily dosing maintains stable inhibition of cholesterol synthesis. Patients should maintain a dosing diary or use reminder systems if forgetfulness becomes recurrent.

Overdose

There is no specific antidote for atorvastatin overdose. Suspected overdose should involve immediate medical consultation. Treatment is supportive and symptomatic, with monitoring of liver function and creatine kinase levels. Gastric lavage may be considered if ingestion occurred within one hour. Hemodialysis is not expected to significantly enhance elimination due to high protein binding. Cases of accidental pediatric ingestion require immediate emergency assessment.

Storage

Store at room temperature between 15-30°C in the original container. Protect from light and moisture. Keep tightly closed and out of reach of children. Do not use if the blister packaging is damaged or tablets show signs of deterioration. Discard any unused medication after the expiration date printed on the packaging. Do not flush medications down the toilet or drain unless instructed to do so.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Atorlip 10 is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and patients should follow their physician’s specific instructions. The manufacturer and distributor are not liable for any consequences arising from the use or misuse of this information.

Reviews

Clinical studies demonstrate that atorvastatin 10 mg achieves LDL-C reduction goals in approximately 60-70% of patients with moderate hypercholesterolemia. The ASCOT-LLA trial showed 36% reduction in coronary events with this dosage in hypertensive patients. Real-world evidence indicates good tolerability profile, with discontinuation rates due to adverse effects below 5% in most populations. Patients report satisfaction with convenience of once-daily dosing and measurable improvements in lipid profiles within 2-4 weeks of initiation.